Acarbose-induced microbiome shifts normalize pain thresholds as a functional readout of biological age

Elena Martínez (PhD)· Mar 21, 2026

Mechanism: Acarbose treatment enriches SCFA-producing gut bacteria, increasing butyrate which activates FFAR2/3 receptors on the vagal nerve to reduce neuroinflammation. Readout: Readout: This normalizes nociceptor sensitization, decreasing heat pain threshold, reducing DNAm age acceleration, and increasing vagal tone in aged mice.

Hypothesis

Acarbose treatment lowers heat pain thresholds in aged mice, reflecting a reversal of epigenetic age acceleration via microbiome-derived SCFA signaling to the vagus nerve.

Mechanistic Rationale

Acarbose enriches SCFA-producing taxa (Bacteroidaceae, Bifidobacteriaceae) -> increased colonic butyrate and acetate.
Butyrate activates FFAR2/3 on afferent vagal fibers, increasing vagal tone and reducing neuroinflammation in the spinal dorsal horn.
Reduced neuroinflammation normalizes nociceptor sensitization, decreasing the heat pain threshold (i.e., increasing pain sensitivity) toward youthful levels.
This functional shift parallels reductions in DNAm age and brain-PAD, positioning pain threshold as a peripheral biomarker of biological age.

Predictions

Old mice (>=20 mo) fed 400 ppm acarbose for 8 weeks will show a significant left-shift in the Hargreaves test (lower latency) relative to age-matched controls.
The magnitude of threshold change will correlate negatively with epigenetic age acceleration (ΔDNAm) and positively with fecal butyrate concentration.
Vagal tone, indexed by heart-rate variability (RMSSD), will increase in parallel with pain-threshold shifts.
Pharmacological blockade of FFAR2/3 (e.g., with GLPG0974) during acarbose treatment will abolish both the pain-threshold normalization and the epigenetic age benefit.

Experimental Design

Groups: young (3 mo) control, old control, old + acarbose, old + acarbose + FFAR2/3 antagonist, old + antagonist alone.
Measurements (baseline and weekly):
- Pain threshold: Hargreaves test (radiant heat latency) and hot-plate latency.
- Microbiome: 16S rRNA sequencing; quantify Bacteroidaceae, Bifidobacteriaceae.
- SCFAs: GC-MS of cecal contents for butyrate, acetate.
- Vagal tone: ECG-derived HRV (RMSSD).
- Epigenetic age: Illumina EPIC array on liver DNA; compute DNAm age and ΔDNAm.
- Neuroinflammation: Iba1 and GFAP immunostaining in spinal cord.
Statistical plan: ANOVA with post-hoc Tukey; Pearson correlation for threshold vs ΔDNAm and butyrate.

Potential Outcomes

If acarbose lowers pain thresholds and this shift tracks with reduced ΔDNAm, the hypothesis is supported, indicating that somatosensory phenotyping can serve as a low-cost, functional aging clock.
If thresholds remain unchanged despite microbiome and epigenetic effects, the link between SCFA-vagal signaling and pain perception is not sufficient to drive behavioral readouts, challenging the notion that pain sensitivity directly mirrors biological age.
Antagonist rescue experiments that block the effect will confirm the mechanistic pathway involving FFAR2/3-mediated vagal signaling.

Mechanistic Rationale

Acarbose enriches SCFA-producing taxa (Bacteroidaceae, Bifidobacteriaceae) -> increased colonic butyrate and acetate.

Butyrate activates FFAR2/3 on afferent vagal fibers, increasing vagal tone and reducing neuroinflammation in the spinal dorsal horn.

Reduced neuroinflammation normalizes nociceptor sensitization, decreasing the heat pain threshold (i.e., increasing pain sensitivity) toward youthful levels.

This functional shift parallels reductions in DNAm age and brain-PAD, positioning pain threshold as a peripheral biomarker of biological age.

Predictions

Old mice (>=20 mo) fed 400 ppm acarbose for 8 weeks will show a significant left-shift in the Hargreaves test (lower latency) relative to age-matched controls.

The magnitude of threshold change will correlate negatively with epigenetic age acceleration (ΔDNAm) and positively with fecal butyrate concentration.

Vagal tone, indexed by heart-rate variability (RMSSD), will increase in parallel with pain-threshold shifts.

Pharmacological blockade of FFAR2/3 (e.g., with GLPG0974) during acarbose treatment will abolish both the pain-threshold normalization and the epigenetic age benefit.

Experimental Design

Groups: young (3 mo) control, old control, old + acarbose, old + acarbose + FFAR2/3 antagonist, old + antagonist alone.

Measurements (baseline and weekly):

Pain threshold: Hargreaves test (radiant heat latency) and hot-plate latency.
Microbiome: 16S rRNA sequencing; quantify Bacteroidaceae, Bifidobacteriaceae.
SCFAs: GC-MS of cecal contents for butyrate, acetate.
Vagal tone: ECG-derived HRV (RMSSD).
Epigenetic age: Illumina EPIC array on liver DNA; compute DNAm age and ΔDNAm.
Neuroinflammation: Iba1 and GFAP immunostaining in spinal cord.

Statistical plan: ANOVA with post-hoc Tukey; Pearson correlation for threshold vs ΔDNAm and butyrate.

Potential Outcomes

If acarbose lowers pain thresholds and this shift tracks with reduced ΔDNAm, the hypothesis is supported, indicating that somatosensory phenotyping can serve as a low-cost, functional aging clock.

If thresholds remain unchanged despite microbiome and epigenetic effects, the link between SCFA-vagal signaling and pain perception is not sufficient to drive behavioral readouts, challenging the notion that pain sensitivity directly mirrors biological age.

Antagonist rescue experiments that block the effect will confirm the mechanistic pathway involving FFAR2/3-mediated vagal signaling.